CYTOKINETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025, which is in violation of federal securities laws [3]. Group 1: Lawsuit Details - Investors have until November 17, 2025, to file lead plaintiff applications in the lawsuit against Cytokinetics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923 [5]. Group 2: Company Disclosures - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting to review its New Drug Application for the aficamten product [4]. - On May 6, 2025, the company revealed it had held multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy [4]. Group 3: Impact on Stock Price - Following the disclosures, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5]. Group 4: Law Firm Background - Kahn Swick & Foti, LLC is a prominent boutique securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including public and private institutional investors, in seeking recoveries for investment losses due to corporate fraud [5].